Loading stock data…
Heron Therapeutics, Inc. (HRTX)
$0.46-0.00 (-0.70%)
Market ClosedLast close Jul 24
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Heron Therapeutics, Inc. in the Healthcare sector is trading at $0.46 with a market capitalization of $82M. Wall Street consensus targets $2.00 (1 analysts), implying a +338.8% move over the next 12 months. The stock is currently near its 52-week low of $0.38, remaining 54.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +338.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $34.71M↓ | $40.59M↑ | $38.21M↑ | $37.20M↓ | $38.90M |
| Gross Profit | $24.07M↓ | $29.47M↑ | $26.30M↓ | $27.34M↓ | $30.45M |
| Operating Income | -$4.76M↓ | $38,000↑ | -$4.09M↓ | -$1.64M↓ | $3.15M |
| Net Income | -$8.11M↓ | -$2.95M↑ | -$17.50M↓ | -$2.38M↓ | $2.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, w...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$82.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-338.63%
Volume
Today's trading volume
1.13M
Recent News
New Strong Sell Stocks for July 15th
BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision
Heron Therapeutics is back in focus after analysts trimmed their fair value price target from US$3.00 to US$2.00 per share, a reset that puts the current debate around the company’s outlook front and center. Much of this shift tracks recent Street commentary following the Cinvanti patent decision, with analysts reassessing downside risk from potential generic competition against any upside from an appeal and execution on the existing portfolio. As you read on, you will see how these changing...
Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Heron Therapeutics, Inc. (NASDAQ:HRTX) is one of the most promising stocks on our list. TheFly reported on June 3 that H.C. Wainwright lowered its price target on HRTX to $2 from $4 while maintaining a Buy rating after the U.S. […]
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% an